Get in touch with us to discuss your project and discover how the Pioneer Antibody Discovery Platform can help identify your new therapeutic candidates.
Speak with a Pioneer Platform ExpertAccelerating Biotherapeutic Antibody Discovery
Pioneer Antibody
Discovery Platform
Unlock the discovery of clinical-quality
candidates in exceptional timelines
Pioneer Antibody Discovery Platform
We deliver a bespoke service of antibody discovery for each client based on their unique requirements. From challenging targets to pH sensitive antibodies and bispecifics, we can help you to accelerate your drug candidate discovery.
We specialise in antibody phage display with over 20 years of antibody expertise.
Our state-of-the-art phage display human antibody library for biotherapeutic antibody discovery combined with over 20 years of expertise, rapidly generates diverse and high-affinity therapeutic leads with excellent developability profiles.
Find out more about Pioneer Platform and SpyLock TechnologyYour Target, Your Biologic
Tailored to your specific needs, our team of specialists accelerates and simplifies your journey to identify functional biologics for your target of interest. A dedicated team of experienced scientists and technical specialists is assigned to each project, delivering a customized service designed to each client’s specifications and success criteria.
The final antibodies are fully mammalian-expressed IgGs, and include a complete data package with functional characterization and sequence.
Clients will receive exclusive ownership of the sequences of the antibody deliverables.
From establishing project-specific functional assays, carrying out library screening, and detailed characterization of clones, our scientists keep clients informed of progress and involved in decision-making. IP transfer of Pioneer-derived biologics from Bio-Rad to clients is based on a fee-for-service model. No requirement for royalties on successful candidates.
From establishing project-specific functional assays, carrying out library screening, and detailed characterization of clones, our scientists keep clients informed of progress and involved in decision-making. IP transfer of Pioneer-derived biologics from Bio-Rad to clients is based on a fee-for-service model. No requirement for royalties on successful candidates.
Clients will receive exclusive ownership of the sequences of the antibody deliverables.
Our Technology
At the heart of the Pioneer Antibody Discovery Platform is the Pioneer Antibody Library — one of the largest functional phage display libraries ever created. The Pioneer Antibody Library has been validated for:
Diversity
■ Exceptional size — more than 200 billion unique antibody sequences
■ High and diverse number of unique hits from standard selection
■ Affinities in the sub-nanomolar range directly from the library
Developability
■ Antibodies use germline sequences with proven performance
■ Reduced motifs that cause developability concerns
■ 96% of sequences encode functional light and heavy chains
■ Excellent flexibility for scalable, tailored formats
Developability
■ Antibodies use germline sequences with proven performance
■ Reduced motifs that cause developability concerns
■ 96% of sequences encode functional light and heavy chains
■ Excellent flexibility for scalable, tailored formats
An exceptionally large, functional phage display Fab antibody library
SpyDisplay Technology
SpyDisplay is an innovative method of phage display that uses SpyTag technology. SpyDisplay is a very efficient system, well suited for the selection of high-affinity antibodies.
SpyTag, a short peptide of 13 amino acids (aa), reacts spontaneously and specifically with a SpyCatcher protein (113 aa) to form an isopeptide bond.
SpyDisplay uses a phagemid-based expression vector which encodes a SpyTagged Fab and a SpyCatcher-pIII integrated into the E. coli genome. In SpyDisplay, the Fab is covalently displayed via SpyTag/SpyCatcher ligation on the filamentous phage carrying the SpyCatcher fused to the pIII coat protein. As SpyDisplay utilizes a single vector for both selections during phage display and expression of clones after screening, it significantly improves workflow efficiency with a less error prone process.
Bispecific Screening
SpyLock Technology
SpyLock is a cutting-edge approach to expediting bispecific screening. It takes advantage of the autocatalytic reaction between SpyTag and SpyCatcher. The Bio-Rad team has introduced a groundbreaking innovation with a 'lockable' SpyCatcher named SpyLock, which can be reversibly inhibited to prevent unwanted ligation with a SpyTag. The simplicity of SpyLock technology is reflected by its sequential antibody reactions for the generation of a bispecific prototype.
A SpyCatcher-SpyLock dimer, the BiLockCatcher, reacts with the first SpyTagged antibody fragment (A in the figure). Then by “unlocking” the second SpyLock site using a reducing agent, the second SpyTagged antibody fragment (B) can be loaded to produce a bispecific. Bio-Rad has developed a protocol that can be performed in 90 minutes, as well as a high purity protocol, which usually yields >95% bispecific antibody. When paired with the Pioneer Antibody Discovery Platform, SpyLock technology emerges as an ideal solution for swiftly generating bispecific antibodies tailored for high-throughput screening.
Key Features of the Pioneer Antibody Discovery Platform
Fully synthetic, fully human Fab antibody library specifically designed to minimize nonproductive cloning artefacts — 96% of sequences encode functional light and heavy chains.
- New Antibody library with exceptional size and broad functional diversity
- Proprietary SpyDisplay technology for accelerated candidate selection
- Prototyping of therapeutic candidates in a multitude of formats with TrailBlazer technology
- Rapid generation of bispecific antibodies for high throughput screening with SpyLock Technology
- Ownership of candidates
- World-class specialists and scientists offering a tailored service to your needs
The Pioneer Antibody Discovery Services will deliver:
A diverse set of clinical quality leads with sub-nanomolar affinities derived from one of the largest functional, fully human, fab output, synthetic phage display libraries in existence.
Screening and testing of various antibody formats using TrailBlazer technology for rapid format prototyping.
Exclusivity and ownership of sequences of antibody deliverables.
Address
Phone
Email